Severe pancytopenia in a patient taking low dose methotrexate and probenecid

K. S. Basin, A. Escalante, T. D. Beardmore

Research output: Contribution to journalArticlepeer-review

63 Scopus citations


A patient with rheumatoid arthritis developed life-threatening pancytopenia resulting from low dose oral methotrexate (MTX) toxicity potentiated by probenecid. Clinically significant drug interactions are not frequently cited as risk factors for MTX hematologic toxicity. As low dose MTX is gaining increasing popularity in the rheumatologic practice, these potentially serious interactions should be considered.

Original languageEnglish (US)
Pages (from-to)609-610
Number of pages2
JournalJournal of Rheumatology
Issue number4
StatePublished - 1991
Externally publishedYes


  • Drug interactions
  • Drug toxicity
  • Methotrexate
  • Pancytopenia
  • Probenecid
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Severe pancytopenia in a patient taking low dose methotrexate and probenecid'. Together they form a unique fingerprint.

Cite this